Therapeutic development, evidence, safety and the rapidly growing market around peptide compounds.
PeptidesVitalspan Wire conceptual illustrationStructure-based screening produced a micromolar-binding candidate with target-dependent antiproliferative activity across several prostate cancer cell lines.
PeptidesVitalspan Wire conceptual illustrationA structure-guided program produced several peptide constructs with improved serum and proteolytic stability, but receptor function remains to be demonstrated.
PeptidesVitalspan Wire conceptual illustrationC3 inhibition reduced astrocyte loss, aquaporin-4 depletion and demyelination in experimental neuromyelitis optica spectrum disorder.
PeptidesVitalspan Wire conceptual illustrationIDR-1002 reduced inflammatory markers, supported mineralization and improved tissue organization in laboratory and rat pulpitis experiments.
PeptidesVitalspan Wire conceptual illustrationThe galanin-family neuropeptide shifted energy balance after central administration and produced an acute intranasal signal in male rats.
PeptidesVitalspan Wire conceptual illustrationThe experimental nanostructure activated Nrf2 in retinal pigment epithelium and preserved retinal integrity for 28 days after one intravitreal injection.
PeptidesVitalspan Wire conceptual illustrationPeptiSleep improved selected questionnaire domains in a small single-blind study, while sleep diaries and several other outcomes did not separate from placebo.
PeptidesVitalspan Wire conceptual illustrationA new field review separates models that identify antimicrobial sequences from those that generate candidates—and details why prediction is not proof of a drug.
PeptidesVitalspan Wire conceptual illustrationThe candidate reduced a METTL3-METTL14 interaction signal and cellular m6A levels, but all antitumor evidence remains in vitro.
PeptidesVitalspan Wire conceptual illustrationThe modular system paired a HER2-targeting engager with localized IL-12, producing stronger immune responses in a model tumor environment.
PeptidesVitalspan Wire conceptual illustrationA clinical review separates established teriparatide use from experimental antimicrobial, cartilage-penetrating and AI-designed peptide platforms.
PeptidesVitalspan Wire conceptual illustrationA 20-person phase 1 trial produced an immune response without severe or serious adverse events, but it was designed to establish an early safety signal—not clinical benefit.
PeptidesVitalspan Wire conceptual illustrationThe 309-patient phase 3 comparison favored lutetium-177 edotreotide for advanced somatostatin-receptor-positive neuroendocrine tumors.
PeptidesVitalspan Wire conceptual illustrationTwo randomized early-stage trials found a roughly 10-day half-life and weight loss of up to 8.6% after 16 weeks, with gastrointestinal events remaining the central tolerability question.
PeptidesVitalspan Wire conceptual illustrationAdding the myostatin antibody apitegromab preserved more lean mass without materially changing total weight loss in a 102-person phase 2 study.
PeptidesVitalspan Wire conceptual illustrationA clean separation of laboratory findings, limited human data and the compound's current regulatory status.